Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist
- PMID: 29230680
- PMCID: PMC5849634
- DOI: 10.1007/s11547-017-0835-6
Structured reporting for fibrosing lung disease: a model shared by radiologist and pulmonologist
Abstract
Objectives: To apply the Delphi exercise with iterative involvement of radiologists and pulmonologists with the aim of defining a structured reporting template for high-resolution computed tomography (HRCT) of patients with fibrosing lung disease (FLD).
Methods: The writing committee selected the HRCT criteria-the Delphi items-for rating from both radiology panelists (RP) and pulmonology panelists (PP). The Delphi items were first rated by RPs as "essential", "optional", or "not relevant". The items rated "essential" by < 80% of the RP were selected for the PP rating. The format of reporting was rated by both RP and PP.
Results: A total of 42 RPs and 12 PPs participated to the survey. In both Delphi round 1 and 2, 10/27 (37.7%) items were rated "essential" by more than 80% of RP. The remaining 17/27 (63.3%) items were rated by the PP in round 3, with 2/17 items (11.7%) rated "essential" by the PP. PP proposed additional items for conclusion domain, which were rated by RPs in the fourth round. Poor consensus was observed for the format of reporting.
Conclusions: This study provides a template for structured report of FLD that features essential items as agreed by expert thoracic radiologists and pulmonologists.
Keywords: Consensus; High-resolution computed tomography; Lung fibrosis; Standardized report; Structured report.
Conflict of interest statement
Conflict of interest
The authors state that this study was not funded. Dr. Albera reports grants, personal fees and non-financial support from Roche, during the conduct of the study; personal fees and non-financial support from Roche, personal fees and non-financial support from Boehringer Ingelheim, personal fees and non-financial support from Fibrogen, personal fees and non-financial support from GSK, personal fees and non-financial support from Sanofi Aventis, outside the submitted work. Dr. Harari reports personal fees from Roche, grants and personal fees from Intermune, grants and personal fees from Boehringer Ingelheim, outside the submitted work. Dr. Luppi reports personal fees from Boehringer Ingelheim, grants and personal fees from Roche, during the conduct of the study. Dr. Odone reports personal fees from Roche, during the conduct of the study. Dr. Silva reports personal fees from Roche, outside the submitted work. Dr. Sverzellati reports personal fees from Roche, personal fees from Boehringer Ingelheim, outside the submitted work. The other authors declare that they have no conflict of interest.
Ethical approval
The manuscript does not contain clinical studies or patient data.
Figures
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
